None approved; preclinical research stage
MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) is a mitochondrial genetic disorder most commonly caused by the m.3243A>G point mutation in the MT-TL1 gene, which encodes mitochondrial transfer RNA for leucine (tRNA-Leu). This mutation accounts for approximately 80% of MELAS cases. The MT-TL1 mutation impairs mitochondrial protein synthesis, reducing the function of the electron transport chain and compromising cellular energy production.
MELAS typically presents before age 40 with recurrent stroke-like episodes, seizures, migraine-like headaches with vomiting, and progressive cognitive decline. Additional features include lactic acidosis, short stature, hearing loss, diabetes, cardiac involvement, and exercise intolerance. The disease affects tissues with high energy demands — particularly the brain, muscles, and heart.
Mitochondrial genetics differs fundamentally from nuclear genetics. Each cell contains hundreds to thousands of mitochondria, each with multiple copies of mitochondrial DNA (mtDNA). In most MELAS patients, both mutant and normal mtDNA coexist within the same cell — a state called heteroplasmy. The proportion of mutant mtDNA determines disease severity. When the mutant load exceeds a threshold (typically 70–90% in affected tissues), mitochondrial dysfunction becomes clinically significant.
This heteroplasmy creates a therapeutic opportunity for allele-selective ASOs. By designing an ASO that specifically targets the mutant mitochondrial RNA (carrying the A>G change) while sparing the wild-type sequence, it may be possible to shift the heteroplasmy ratio by preferentially degrading mutant transcripts. Even a modest reduction in the proportion of mutant mtDNA transcripts could push cells below the pathogenic threshold, restoring sufficient mitochondrial function.
ASO therapy for mitochondrial diseases faces unique challenges. Mitochondria have a double-membrane structure, and delivering ASOs into the mitochondrial matrix requires overcoming these barriers. Research is ongoing into chemical modifications and delivery strategies that enhance mitochondrial uptake. Additionally, the single-nucleotide difference between mutant and wild-type sequences demands high allele selectivity in the ASO design.
Despite these challenges, the potential impact of shifting heteroplasmy makes this an active area of research. Preclinical studies have demonstrated that ASOs can discriminate between mutant and wild-type mitochondrial sequences and achieve selective knockdown.
Pequliar designs allele-selective ASO candidates for MELAS syndrome, optimizing for discrimination between the mutant m.3243A>G and wild-type sequences. The platform scores candidates for binding affinity, mismatch discrimination, and off-target safety, providing synthesis-ready sequences for research and preclinical evaluation. Given the early stage of mitochondrial ASO delivery research, experimental validation of both efficacy and mitochondrial uptake is essential.
Describe your mutation and get ranked, synthesis-ready ASO candidates in minutes. $399 per design.
Start a designPequliar is a computational research tool for informational purposes only. All sequences are computationally predicted candidates that have not been experimentally validated. Pequliar does not prescribe, recommend, or administer any compound. Independent validation by qualified professionals is required.